Ocugen Inc OCGN

NAS: OCGN | ISIN: US67577C1053   17/05/2024
1,910 USD (-3,54%)
(-3,54%)   17/05/2024

25 september 2021 · OCUGEN INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Ocugen, Inc. - OCGN · Persbericht

13 augustus 2021 · DEADLINE NEXT TUESDAY: Shareholders with Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN · Persbericht

4 augustus 2021 · SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN · Persbericht

29 juli 2021 · SHAREHOLER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ocugen, Inc. of Class Action Lawsuit and Upcoming Deadline - OCGN · Persbericht

17 juli 2021 · Pomerantz Law Firm Announces the Filing of a Class Action Against Ocugen, Inc. and Certain Officers - OCGN · Persbericht

13 juli 2021 · OCUGEN INVESTOR NOTICE: Investors With Substantial Losses Have Opportunity to Lead the Ocugen, Inc. Class Action Lawsuit - OCGN · Persbericht

19 juni 2021 · Moore Kuehn, PLLC Encourages Investors of FREQ, ACRX, or OCGN to Contact Law Firm · Persbericht

3 mei 2021 · Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2   · Persbericht

18 maart 2021 · Ocugen Provides Business Update and Full Year 2020 Financial Results · Persbericht

12 maart 2021 · Ocugen to Host Conference Call on Thursday, March 18 at 8:30 a.m. ET to Discuss 2020 Financial Results and Provide a Business Update · Persbericht

8 maart 2021 · Ocugen Inc. to Present at Upcoming March Investor Conferences · Persbericht

23 februari 2021 · European Commission Grants Ocugen Orphan Medicinal Product Designation for Gene Therapy Product Candidate, OCU400, For the Treatment of Both Retinitis Pigmentosa and Leber Congenital Amaurosis · Persbericht

11 februari 2021 · Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock · Persbericht

8 februari 2021 · Ocugen Inc. Announces $23 Million Registered Direct Offering of Common Stock Priced at a Premium to Market · Persbericht

2 februari 2021 · Ocugen and Bharat Biotech Announce Execution of Definitive Agreement for the Commercialization of COVAXIN™ in the US Market · Persbericht

12 januari 2021 · Ocugen Inc. Announces the Cancellation of Stockholder Meeting Previously Adjourned to 11:00 a.m. Eastern Time on January 13, 2021 · Persbericht

8 januari 2021 · Ocugen Inc. Regains Compliance with Nasdaq Bid Price Rule · Persbericht

Mijn selecties